Institution Directory

Clinical trials at Northwestern Medicine

Sites in Chicago, IL

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 10:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1126

Shown on this page

Current sort

Live official records

Conditions: Mitral Valve Insufficiency
Interventions: Twelve TMVR Implant, Medtronic Intrepid™ Transcatheter Transfemoral Mitral Valve Replacement System; Device
Lead sponsor: Medtronic Cardiovascular; Industry
Eligibility: 18 Years and older
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 21
States / cities: Phoenix, Arizona • Los Angeles, California • Atlanta, Georgia + 12 more

Conditions: Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Interventions: Not listed
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Enrollment: 150,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2030
U.S. locations: 63
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more

Conditions: Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
Interventions: CNTY-101, IL-2, Lymphodepleting Chemotherapy; Biological · Drug
Lead sponsor: Century Therapeutics, Inc.; Industry
Eligibility: 17 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Sacramento, California • Chicago, Illinois + 3 more

Conditions: Low Back Pain
Interventions: Embedded Emergency Department Physical Therapy, Usual Care; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Chicago, Illinois • Salt Lake City, Utah

Conditions: Small Cell Lung Cancer (SCLC)
Interventions: Tarlatamab, Lurbinectedin, Topotecan, Amrubicin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 509 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 25
States / cities: Mobile, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 19 more

Conditions: Heart Valve Diseases, Aortic Valve Insufficiency
Interventions: TAVR; Procedure
Lead sponsor: Duk-Woo Park, MD; Other
Eligibility: 19 Years and older
Enrollment: 10,000 participants
Timeline: 2019 – 2036
U.S. locations: 2
States / cities: Stanford, California • Chicago, Illinois

Conditions: Lung Cancer, NSCLC
Interventions: Atezolizumab, Docetaxel, Cisplatin, Pemetrexed; Drug
Lead sponsor: Nasser Hanna; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 9
States / cities: Chicago, Illinois • Indianapolis, Indiana • Berkeley Heights, New Jersey + 6 more

Conditions: Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
Interventions: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment; Biological · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2028
U.S. locations: 680
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more

Conditions: Hip Dysplasia
Interventions: PAO with hip arthroscopy, PAO without hip arthroscopy; Procedure
Lead sponsor: Ottawa Hospital Research Institute; Other
Eligibility: 16 Years to 50 Years
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 4
States / cities: Chicago, Illinois • Royal Oak, Michigan • St Louis, Missouri + 1 more

Conditions: Atopic Dermatitis
Interventions: Placebo, Upadacitinib, Topical corticosteroids (TCS); Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 1,533 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 59
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more

Conditions: Prostate Cancer
Interventions: Enzalutamide, LY2157299; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • Baltimore, Maryland

Conditions: ALK Gene Rearrangement, ALK Gene Translocation, ALK Positive, Stage IB Non-Small Cell Lung Carcinoma AJCC v7, Stage II Non-Small Cell Lung Cancer AJCC v7, Stage IIA Non-Small Cell Lung Carcinoma AJCC v7, Stage IIB Non-Small Cell Lung Carcinoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7
Interventions: Clinical Observation, Crizotinib, Laboratory Biomarker Analysis; Other · Drug
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2036
U.S. locations: 1613
States / cities: Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 978 more

About this Northwestern Medicine institution page

What this page lists: ClinicalTrials.gov records that list Northwestern Medicine in Chicago, IL as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Northwestern Medicine

Filter and sort this campus

Live official records

Transcatheter Mitral Valve Replacement System (TMVR) Pilot Study and The Early Feasibility Study of the TMVR Transseptal System

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

A Multi-Site Feasibility Trial of Embedded Emergency Department Physical Therapy

Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

Transpacific TAVR Registry

Adjuvant Treatment With Cisplatin-based Chemotherapy Plus Concomitant Atezolizumab in Patients With Stage I (Tumors ≥ 4cm), IIA, IIB, and Select Stage III [Any T1-3 N1-2 and T4N0-2] Resected Non-small Cell Lung Cancer (NSCLC) and the Clearance of Circulating Tumor DNA (ctDNA)

Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

Study of TGF-β Receptor Inhibitor Galunisertib (LY2157299) and Enzalutamide in Metastatic Castration-resistant Prostate Cancer

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

About this Northwestern Medicine institution page